跳到正文
原文
Editas Medicine· @editasmed · X·· 2026-05-15AI 评分18
AI 导读

本周在#ASGCT2026上,我们展示了新的临床前数据,支持我们领先的体内开发候选药物EDIT-401的持续推进,以及我们差异化上调策略的更广泛潜力。查看报告:https://bit.ly/3RbSqFI。

正文

This week at #ASGCT2026, we presented new preclinical data supporting the continued advancement of our lead in vivo development candidate, EDIT-401, as well as the broader potential of our differentiated upregulation strategy. View the presentations here: https://bit.ly/3RbSqFI.

来源:Editas Medicine · x.com